Pharmaceutical Investing Antibe Therapeutics Announces Successful Completion of Part One of Phase 2B Dose-Ranging, Efficacy Study for ATB-346
Pharmaceutical Investing Antibe Therapeutics Receives Approval to Initiate Part Two of Phase 2B Dose-Ranging, Efficacy Study for ATB-346
Noble Mineral highlights Successful Exploration Results announced by Canada Nickel, including Highest Grade to Date at Mann West
